GILD - Gilead Sciences, Inc.
| Previous Close | 66.99 |
| Open | 66.91 |
| Bid | 66.25 x 800 |
| Ask | 66.64 x 1200 |
| Day's Range | 66.20 - 66.98 |
| 52 Week Range | 60.32 - 79.61 |
| Volume | 5,333,804 |
| Avg. Volume | 6,662,188 |
| Market Cap | 84.38B |
| Beta (3Y Monthly) | 1.14 |
| PE Ratio (TTM) | 14.64 |
| EPS (TTM) | 4.53 |
| Earnings Date | Jul 23, 2019 - Jul 29, 2019 |
| Forward Dividend & Yield | 2.52 (3.87%) |
| Ex-Dividend Date | 2019-06-13 |
| 1y Target Est | 79.81 |
- Motley Fool•20 hours ago
Better Buy: Aurora Cannabis vs. Gilead Sciences
Between this unlikely pair, which stock is the better pick for long-term investors?
- Zacks•3 days ago
GILD vs. ILMN: Which Stock Is the Better Value Option?
GILD vs. ILMN: Which Stock Is the Better Value Option?
- Motley Fool•3 days ago
3 Top Dividend Stocks to Buy in June
Here's why it could be the perfect time to add these income stocks to your portfolio.
- Zacks•5 days ago
Galapagos Ends Enrollment in Osteoarthritis Study Before Time
Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.
- Zacks•5 days ago
CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.
- Zacks•5 days ago
Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
Is (GILD) Outperforming Other Medical Stocks This Year?
- CNW Group•7 days ago
GT Biopharma Company Update
TAMPA, Florida , June 10, 2019 /CNW/ -- GT Biopharma, Inc. (OTCQB: GTBP) (OTCQB: GTBP.PA) an immuno-oncology company focused on innovative treatments based on the Company's proprietary NK cell engager ...
- Simply Wall St.•8 days ago
Here's How We Evaluate Gilead Sciences, Inc.'s (NASDAQ:GILD) Dividend
Dividend paying stocks like Gilead Sciences, Inc. (NASDAQ:GILD) tend to be popular with investors, and for good reason...
- Zacks•12 days ago
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
- Zacks•13 days ago
5 Biotech Stocks to Buy Right Now
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.
- Motley Fool•13 days ago
3 Cancer Stocks Given a Lift by Amgen
Success with an experimental new oncology treatment that scratches a 35-year itch is good news for more than one biotech stock.
- Reuters•14 days ago
US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag
The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators. While the sell-off in the internet heavyweights was the biggest drag on the Nasdaq, the index has been falling steadily since its May 3 record closing high as investors worried about slowing global growth amid an escalating U.S.-China trade war. The S&P 500 had a volatile session and ended the day down 0.3 percent, but the Dow Jones Industrial Average ended the session virtually unchanged.
- Zacks•14 days ago
Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO
Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.
- Business Wire•14 days ago
Kite Announces New Yescarta® Data From ZUMA-1
-- Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment --
- Business Wire•16 days ago
Kite Announces End of Phase 1 ZUMA-3 Results for KTE-X19 in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia
ZUMA-3 is a single-arm Phase 1/2 study in adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The results provide guidance on dosing and safety management for KTE-X19 to inform the ongoing Phase 2 study. Patients enrolled in this study were primary refractory or relapsed/refractory after at least two prior lines of therapy.
- Zacks•16 days ago
Why Is Gilead (GILD) Down 3% Since Last Earnings Report?
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Market Realist•17 days agoWhat Are Gilead Sciences’ Key Growth Drivers in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Growth driversSince the second quarter of 2016, Gilead Sciences (GILD) has been reporting major YoY (year-over-year) revenue declines, mainly due to its lower HCV
- GlobeNewswire•17 days ago
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (axicabtagene ciloleucel) With lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kite, a Gilead Company (GILD) and Humanigen, Inc., (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Kite will act as the sponsor of this study and will be responsible for its conduct. GM-CSF has been identified, through clinical correlative analysis and preclinical modeling, as a potential key signal in the inflammatory cascade triggering toxicities associated with chimeric antigen receptor T (CAR T) cell therapy.1 Toxicities associated with CAR T therapy include neurologic toxicity and cytokine release syndrome (CRS).
- Business Wire•17 days ago
Kite and Humanigen Announce Clinical Collaboration to Evaluate Investigational Combination of Yescarta® (Axicabtagene Ciloleucel) with Lenzilumab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Kite, a Gilead Company (GILD), and Humanigen, Inc. (HGEN) announced today the formation of a clinical collaboration to conduct a Phase 1/2 study of lenzilumab, an investigational anti-GM-CSF monoclonal antibody, with Yescarta® (axicabtagene ciloleucel) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Kite will act as the sponsor of this study and will be responsible for its conduct. GM-CSF has been identified, through clinical correlative analysis and preclinical modeling, as a potential key signal in the inflammatory cascade triggering toxicities associated with chimeric antigen receptor T (CAR T) cell therapy.1 Toxicities associated with CAR T therapy include neurologic toxicity and cytokine release syndrome (CRS).
Market Realist•17 days agoHow Is Biogen’s Tecfidera Positioned in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)MS revenue performance in the first quarterIn the first quarter, Biogen (BIIB) reported MS (multiple sclerosis) franchise revenue of ~$2.1 billion including
Market Realist•17 days agoHow Is Gilead Sciences Revamping Its NASH Strategy in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)NASH failed trialsOn February 11, Gilead Sciences (GILD) issued a press release announcing the top line results from its Phase 3 STELLAR-4 study evaluating the
Market Realist•18 days agoHow Is Biogen’s Alzheimers’ Disease Pipeline Positioned in 2019?
Gilead Sciences or Biogen: Which Is the Better Biotech Pick?(Continued from Prior Part)Failed programOn March 21, Biogen (BIIB) issued a press release announcing the discontinuation of its Phase 3 trials ENGAGE and EMERGE evaluating its leading
- Zacks•18 days ago
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
Gilead Sciences (GILD) closed the most recent trading day at $63.34, moving -0.05% from the previous trading session.
- Business Wire•19 days ago
Gilead and Galapagos to Present Latest Data on Filgotinib at the Annual European Congress of Rheumatology (EULAR 2019)
Gilead Sciences, Inc. (GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that data on filgotinib, an investigational, oral, selective JAK1 inhibitor, will be presented at the Annual European Congress of Rheumatology (EULAR 2019) in Madrid, Spain, on June 12-15, 2019. Among the abstracts to be presented are 24 week interim results from the ongoing FINCH 1 and FINCH 3 Phase 3 studies evaluating filgotinib in adults with rheumatoid arthritis.
- Zacks•19 days ago
GILD or ILMN: Which Is the Better Value Stock Right Now?
GILD vs. ILMN: Which Stock Is the Better Value Option?
